Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 476

1.

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials.

Morabito A, Piccirillo MC, Maione P, Luciani A, Cavanna L, Bonanno L, Filipazzi V, Leo S, Cinieri S, Morgillo F, Burgio MA, Ferrara D, Rosetti F, Bianco R, Artioli F, Cortinovis D, Gebbia V, Fregoni V, Mencoboni M, Sandomenico C, Rossi A, Montanino A, Manzo A, Rocco G, Arenare L, Daniele G, Signoriello S, Gallo C, Perrone F, Gridelli C.

Lung Cancer. 2019 Jul;133:62-68. doi: 10.1016/j.lungcan.2019.05.009. Epub 2019 May 9.

PMID:
31200830
2.

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.

Perrone F, De Laurentiis M, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribecco AS, Putzu C, Del Mastro L, Rossi E, Tinessa V, Mosconi AM, Nuzzo F, Di Rella F, Gravina A, Iodice G, Landi G, Pacilio C, Forestieri V, Lauria R, Fabbri A, Ibrahim T, De Maio E, Barni S, Gori S, Simeon V, Arenare L, Daniele G, Piccirillo MC, Normanno N, de Matteis A, Gallo C.

Eur J Cancer. 2019 Jun 1. pii: S0959-8049(19)30297-7. doi: 10.1016/j.ejca.2019.05.004. [Epub ahead of print]

PMID:
31164265
3.

Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach.

Perrone F, Di Maio M, Efficace F, Gallo C, Giannarelli D, Montesarchio V, Riva S.

J Oncol Pract. 2019 May 24:JOP1900200. doi: 10.1200/JOP.19.00200. [Epub ahead of print] No abstract available.

PMID:
31125283
4.

PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.

Cavalieri S, Perrone F, Milione M, Bianco A, Alfieri S, Locati LD, Bergamini C, Resteghini C, Galbiati D, Platini F, Licitra L, Bossi P.

Oncology. 2019 May 21:1-7. doi: 10.1159/000500246. [Epub ahead of print]

PMID:
31112973
5.

Sperm selection with density gradient centrifugation and swim up: effect on DNA fragmentation in viable spermatozoa.

Muratori M, Tarozzi N, Carpentiero F, Danti S, Perrone FM, Cambi M, Casini A, Azzari C, Boni L, Maggi M, Borini A, Baldi E.

Sci Rep. 2019 May 16;9(1):7492. doi: 10.1038/s41598-019-43981-2.

6.

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

Ascierto PA, Bruzzi P, Eggermont A, Hamid O, Tawbi HA, van Akkooi A, Testori A, Caracò C, Puzanov I, Perrone F.

J Transl Med. 2019 May 10;17(1):148. doi: 10.1186/s12967-019-1892-5.

7.

Identification of potentially druggable molecular alterations in skin adnexal malignancies.

Cavalieri S, Busico A, Capone I, Conca E, Dallera E, Quattrone P, Licitra L, Pruneri G, Bossi P, Perrone F.

J Dermatol. 2019 Jun;46(6):507-514. doi: 10.1111/1346-8138.14889. Epub 2019 Apr 30.

PMID:
31038235
8.

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.

Daniele G, Arenare L, Scambia G, Pisano C, Sorio R, Breda E, De Placido S, Savarese A, Ferrandina G, Raspagliesi F, Panici PB, Ferro A, Rimanti A, Cormio G, Lorusso D, Cecere SC, Scalone S, Marsico VA, Cardalesi C, Cognetti F, Salutari V, Attademo L, Guizzaro L, Schettino C, Piccirillo MC, Perrone F, Gallo C, Pignata S.

Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)30507-4. doi: 10.1016/j.ygyno.2019.04.012. [Epub ahead of print]

PMID:
31029508
9.

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Savarese A, Valabrega G, Pisano C, Salutari V, Raspagliesi F, Kopf B, Cecere SC, Amadio G, Maltese G, Di Napoli M, Greggi S, Signoriello S, Daniele G, Sacco A, Losito S, Normanno N, Perrone F, Gallo C, Piccirillo MC; MITO Investigators.

Gynecol Oncol. 2019 Jun;153(3):535-540. doi: 10.1016/j.ygyno.2019.03.260. Epub 2019 Apr 9.

PMID:
30979589
10.

MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer.

Biamonte F, Santamaria G, Sacco A, Perrone FM, Di Cello A, Battaglia AM, Salatino A, Di Vito A, Aversa I, Venturella R, Zullo F, Costanzo F.

Sci Rep. 2019 Apr 5;9(1):5668. doi: 10.1038/s41598-019-42221-x.

11.

Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?

Cavalieri S, Platini F, Bergamini C, Resteghini C, Galbiati D, Bossi P, Perrone F, Tamborini E, Quattrone P, Licitra L, Locati LD, Alfieri S.

Expert Opin Investig Drugs. 2019 May;28(5):435-443. doi: 10.1080/13543784.2019.1598376. Epub 2019 Apr 4. Review.

PMID:
30897975
12.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.

Clin Lung Cancer. 2019 Feb 21. pii: S1525-7304(19)30025-7. doi: 10.1016/j.cllc.2019.02.006. [Epub ahead of print]

PMID:
30885550
13.

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients.

Rachiglio AM, Fenizia F, Piccirillo MC, Galetta D, Crinò L, Vincenzi B, Barletta E, Pinto C, Ferraù F, Lambiase M, Montanino A, Roma C, Ludovini V, Montagna ES, De Luca A, Rocco G, Botti G, Perrone F, Morabito A, Normanno N.

Cancers (Basel). 2019 Mar 10;11(3). pii: E341. doi: 10.3390/cancers11030341.

14.

A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes.

De Cecco L, Serafini MS, Facco C, Granata R, Orlandi E, Fallai C, Licitra L, Marchesi E, Perrone F, Pilotti S, Quattrone P, Piazza C, Sessa F, Turri-Zanoni M, Battaglia P, Castelnuovo P, Antognoni P, Canevari S, Bossi P.

Oral Oncol. 2019 Mar;90:94-101. doi: 10.1016/j.oraloncology.2019.02.003. Epub 2019 Feb 11.

15.

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.

Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F.

Sci Rep. 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3.

16.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C.

J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.

17.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.

Oncologist. 2019 Feb 22. pii: theoncologist.2018-0618. doi: 10.1634/theoncologist.2018-0618. [Epub ahead of print]

PMID:
30796151
18.

Reply to the letter to the editor 'On the underreporting of health-related quality of life and regulatory approval' by Bhamidipati et al.

Di Maio M, Marandino L, Perrone F.

Ann Oncol. 2019 Apr 1;30(4):658-659. doi: 10.1093/annonc/mdz035. No abstract available.

PMID:
30698648
19.

Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck.

Mirabile A, Miceli R, Calderone RG, Locati L, Bossi P, Bergamini C, Granata R, Perrone F, Mariani L, Licitra L.

Head Neck. 2019 Jun;41(6):1895-1902. doi: 10.1002/hed.25636. Epub 2019 Jan 16.

PMID:
30652392
20.

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.

Pascarella G, Capasso A, Nardone A, Triassi M, Pignata S, Arenare L, Ascierto P, Curvietto M, Maiolino P, D'Aniello R, Montanino A, Laudato F, De Feo G, Botti G, Perrone F, Petrillo A, Cavalcanti E, Lastoria S, Maurea N, Morabito A.

PLoS One. 2019 Jan 8;14(1):e0210330. doi: 10.1371/journal.pone.0210330. eCollection 2019.

21.

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases.

Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V.

Clin Colorectal Cancer. 2019 Mar;18(1):34-43.e6. doi: 10.1016/j.clcc.2018.11.004. Epub 2018 Nov 24.

PMID:
30558859
22.

Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.

Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, Pusceddu S.

Cancer Treat Rev. 2019 Jan;72:45-55. doi: 10.1016/j.ctrv.2018.11.001. Epub 2018 Nov 10. Review.

PMID:
30476750
23.

Honey dressing on a leg ulcer with tendon exposure in a patient with type 2 diabetes.

Teobaldi I, Stoico V, Perrone F, Bruti M, Bonora E, Mantovani A.

Endocrinol Diabetes Metab Case Rep. 2018;2018. pii: EDM180117. doi: 10.1530/EDM-18-0117. Epub 2018 Nov 16.

24.

Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.

Marandino L, La Salvia A, Sonetto C, De Luca E, Pignataro D, Zichi C, Di Stefano RF, Ghisoni E, Lombardi P, Mariniello A, Reale ML, Trevisi E, Leone G, Muratori L, Marcato M, Bironzo P, Novello S, Aglietta M, Scagliotti GV, Perrone F, Di Maio M.

Ann Oncol. 2018 Dec 1;29(12):2288-2295. doi: 10.1093/annonc/mdy449.

25.

Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study.

Signoroni S, Tibiletti MG, Ricci MT, Milione M, Perrone F, Pensotti V, Chiaravalli AM, Carnevali I, Morabito A, Bertario L, Vitellaro M.

Tumori. 2019 Feb;105(1):76-83. doi: 10.1177/0300891618792460. Epub 2018 Aug 17.

PMID:
30117378
26.

Cutaneous squamous carcinoma in a patient with diabetic foot: an unusual evolution of a frequent complication.

Mantovani A, Teobaldi I, Stoico V, Perrone F, Zannoni M, Cima L, Bruti M, Mingolla L, Trombetta M, Bonora E.

Endocrinol Diabetes Metab Case Rep. 2018 Jul 31;2018. pii: 18-0065. doi: 10.1530/EDM-18-0065. eCollection 2018.

27.

From Traumatic Childhood to Cocaine Abuse: The Critical Function of the Immune System.

Lo Iacono L, Catale C, Martini A, Valzania A, Viscomi MT, Chiurchiù V, Guatteo E, Bussone S, Perrone F, Di Sabato P, Aricò E, D'Argenio A, Troisi A, Mercuri NB, Maccarrone M, Puglisi-Allegra S, Casella P, Carola V.

Biol Psychiatry. 2018 Dec 15;84(12):905-916. doi: 10.1016/j.biopsych.2018.05.022. Epub 2018 Jun 11.

PMID:
30029767
28.

Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.

Gridelli C, Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, Filipazzi V, Leo S, Cinieri S, Ciardiello F, Burgio MA, Bilancia D, Cortinovis D, Rosetti F, Bianco R, Gebbia V, Artioli F, Bordonaro R, Fregoni V, Mencoboni M, Nelli F, Riccardi F, di Isernia G, Costanzo R, Rocco G, Daniele G, Signoriello S, Piccirillo MC, Gallo C, Perrone F.

J Clin Oncol. 2018 Sep 1;36(25):2585-2592. doi: 10.1200/JCO.2017.76.8390. Epub 2018 Jul 20.

PMID:
30028656
29.

Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis.

Colombo C, Urbini M, Astolfi A, Collini P, Indio V, Belfiore A, Paielli N, Perrone F, Tarantino G, Palassini E, Fiore M, Pession A, Stacchiotti S, Pantaleo MA, Gronchi A.

Genes Chromosomes Cancer. 2018 Oct;57(10):495-503. doi: 10.1002/gcc.22644. Epub 2018 Aug 20.

PMID:
29901254
30.

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F.

Ann Oncol. 2018 Aug 1;29(8):1800-1806. doi: 10.1093/annonc/mdy197.

PMID:
29860358
31.

Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis.

Perrone F, Cacace R, Van Mossevelde S, Van den Bossche T, De Deyn PP, Cras P, Engelborghs S, van der Zee J, Van Broeckhoven C.

Neurobiol Aging. 2018 Sep;69:292.e7-292.e14. doi: 10.1016/j.neurobiolaging.2018.04.015. Epub 2018 May 9.

32.

Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.

Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P.

Eur J Cancer. 2018 Jul;97:7-15. doi: 10.1016/j.ejca.2018.04.004. Epub 2018 May 4.

PMID:
29734047
33.

Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers.

Resteghini C, Perrone F, Miceli R, Bergamini C, Alfieri S, Orlandi E, Guzzo M, Granata R, Galbiati D, Cavalieri S, Locati L, Licitra L, Bossi P.

Tumori. 2018 Jun;104(3):213-220. doi: 10.1177/0300891618765558. Epub 2018 Apr 18.

PMID:
29714670
34.

Patient-reported outcome measures (PROMs) in patients undergoing patellofemoral arthroplasty and total knee replacement: A comparative study.

Perrone FL, Baron S, Suero EM, Lausmann C, Kendoff D, Zahar A, Gehrke T, Citak M.

Technol Health Care. 2018;26(3):507-514. doi: 10.3233/THC-181185.

PMID:
29614710
35.

Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness.

Farra R, Musiani F, Perrone F, Čemažar M, Kamenšek U, Tonon F, Abrami M, Ručigaj A, Grassi M, Pozzato G, Bonazza D, Zanconati F, Forte G, El Boustani M, Scarabel L, Garziera M, Russo Spena C, De Stefano L, Salis B, Toffoli G, Rizzolio F, Grassi G, Dapas B.

Molecules. 2018 Mar 28;23(4). pii: E777. doi: 10.3390/molecules23040777. Review.

36.

Predictivity of clinical, laboratory and imaging findings in diagnostic definition of palpable thyroid nodules. A multicenter prospective study.

Chiofalo MG, Signoriello S, Fulciniti F, Avenia N, Ristagno S, Lombardi CP, Nicolosi A, Pelizzo MR, Perigli G, Polistena A, Panebianco V, Bellantone R, Calò PG, Boschin IM, Badii B, Di Maio M, Gallo C, Perrone F, Pezzullo L.

Endocrine. 2018 Jul;61(1):43-50. doi: 10.1007/s12020-018-1577-5. Epub 2018 Mar 22.

37.

Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.

Minna E, Romeo P, Dugo M, De Cecco L, Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, Greco A, Borrello MG.

Oncotarget. 2018 Feb 23;9(15):12534. doi: 10.18632/oncotarget.24557. eCollection 2018 Feb 23.

38.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators.

Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29482983
39.

Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.

Piccirillo MC, Scambia G, Bologna A, Signoriello S, Vergote I, Baumann K, Lorusso D, Murgia V, Sorio R, Ferrandina G, Sacco C, Cormio G, Breda E, Cinieri S, Natale D, Mangili G, Pisano C, Cecere SC, Di Napoli M, Salutari V, Raspagliesi F, Arenare L, Bergamini A, Bryce J, Daniele G, Gallo C, Pignata S, Perrone F.

Ann Oncol. 2018 May 1;29(5):1189-1194. doi: 10.1093/annonc/mdy062.

PMID:
29462248
40.

Corrigendum: Correction of the First Author's Affiliation. Outcome of Colorectal Surgery in Elderly Populations.

Shalaby M, Di Lorenzo N, Franceschilli L, Perrone F, Angelucci GP, Quaresima S, Gaspari AL, Sileri P.

Ann Coloproctol. 2017 Dec;33(6):254. doi: 10.3393/ac.2017.33.6.254. Epub 2017 Dec 31.

41.

Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?

Bossi P, Siano M, Bergamini C, Cossu Rocca M, Sponghini AP, Giannoccaro M, Tonella L, Paoli A, Marchesi E, Perrone F, Pilotti S, Locati LD, Canevari S, Licitra L, De Cecco L.

Dis Markers. 2017;2017:6870614. doi: 10.1155/2017/6870614. Epub 2017 Nov 12.

42.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M.

Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5.

43.

Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.

Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Perrone F, Nicolai N, Catanzaro M, Biasoni D, Torelli T, Piva L, Stagni S, Salvioni R, Mariani L, Colecchia M.

Clin Genitourin Cancer. 2018 Apr;16(2):e403-e410. doi: 10.1016/j.clgc.2017.09.016. Epub 2017 Oct 7.

PMID:
29111177
44.

A Novel TetR-Like Transcriptional Regulator Is Induced in Acid-Nitrosative Stress and Controls Expression of an Efflux Pump in Mycobacteria.

Perrone F, De Siena B, Muscariello L, Kendall SL, Waddell SJ, Sacco M.

Front Microbiol. 2017 Oct 23;8:2039. doi: 10.3389/fmicb.2017.02039. eCollection 2017.

45.

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.

Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud F, Falcone A, Pietrantonio F.

Ann Oncol. 2017 Dec 1;28(12):3009-3014. doi: 10.1093/annonc/mdx546.

PMID:
29045518
46.

In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating.

Volpi CC, Ciniselli CM, Gualeni AV, Plebani M, Alfieri S, Verderio P, Locati L, Perrone F, Quattrone P, Carbone A, Pilotti S, Gloghini A.

Hum Pathol. 2018 Apr;74:32-42. doi: 10.1016/j.humpath.2017.09.011. Epub 2017 Oct 6.

PMID:
28993274
47.

Uncommon somatic mutations in metastatic NUT midline carcinoma.

Cavalieri S, Stathis A, Fabbri A, Sonzogni A, Perrone F, Tamborini E, Pelosi G, de Braud F, Platania M.

Tumori. 2017 Nov 15;103(Suppl. 1):e5-e8. doi: 10.5301/tj.5000685.

PMID:
28967088
48.

Angiogenesis Inhibitors in NSCLC.

Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, Piccirillo MC, Daniele G, Perrone F, Rocco G, Morabito A.

Int J Mol Sci. 2017 Sep 21;18(10). pii: E2021. doi: 10.3390/ijms18102021. Review.

49.

First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.

Necchi A, Lo Vullo S, Perrone F, Raggi D, Giannatempo P, Calareso G, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Togliardi E, Colecchia M, Busico A, Gloghini A, Testi A, Mariani L, Salvioni R.

BJU Int. 2018 Mar;121(3):348-356. doi: 10.1111/bju.14013. Epub 2017 Oct 4.

50.

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.

Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, Leighl N, Maione P, Morabito A, Liu G, Tsao MS, Perrone F, Gridelli C.

Oncotarget. 2017 Feb 25;8(34):57528-57536. doi: 10.18632/oncotarget.15725. eCollection 2017 Aug 22.

Supplemental Content

Loading ...
Support Center